6533b7d4fe1ef96bd12629a3

RESEARCH PRODUCT

Subtyping panic disorder by major depression and avoidance behaviour and the response to active treatment

Martin RothWolfgang MaierR. BullerN. ArgyleSydney BrandonOtto BenkertRaben Rosenberg

subject

AdultMaleImipraminemedicine.medical_specialtySocial Environmentbehavioral disciplines and activitiesImipraminelaw.inventionDouble-Blind MethodRandomized controlled triallawmental disordersmedicineHumansPharmacology (medical)PsychiatryAgoraphobiaBiological PsychiatryDepression (differential diagnoses)Psychiatric Status Rating ScalesDepressive DisorderAlprazolamPanic disorderPanicGeneral MedicinePrognosismedicine.diseaseAnxiety DisordersPanichumanitiesSubtypingPsychiatry and Mental healthAlprazolamFemalemedicine.symptomPsychologymedicine.drugAgoraphobiaClinical psychology

description

In order to establish the clinical validity of currently used ways of subtyping panic disorder the predictive power of associated current avoidance behaviour and (secondary) major depression for the response to active treatment (alprazolam, imipramine) was tested. The analysis was based on the data from the Cross-National-Collaborative-Panic-Study. Limited support for validity evidenced by predicting drug response was found for grading panic disorder by the severity of avoidance behaviour; patients with panic attacks and agoraphobia are more responsive to imipramine (compared with alprazolam) when using the reduction of the total number of panic attacks (or of spontaneous panic attacks) as the outcome criterion; patients without any avoidance behaviour did better with alprazolam (compared with imipramine).

https://doi.org/10.1007/bf02193750